European arm of Samaritan Pharmaceuticals Inc has received notification by the National Pharmaceuticals Organization, (EOF) for a new marketing authorization for Amphocil in Greece.

The National Pharmaceutical Organization, (EOF), is the competent authority for granting approval to market pharmaceutical and medical products in Greece, similar to the FDA in the United States.

Samaritan Pharmaceuticals Europe SA is currently in the process of making a pricing application with the Minister of Development who issues official prices with the consent of the Minister of Health. A nine-member Pricing Committee is responsible for providing expert non-binding advice on pharmaceutical prices.

Samaritan will launch the product in the Greek market, once price approval is obtained.
Samaritan established its European headquarters in Athens, Greece to allow access to the markets of East Europe, Asia and African regions with a high proportion of HIV patients, a target population for the advanced drug SP-01A.

Samaritan Pharmaceuticals Europe is currently building, a sales and marketing infrastructure to create revenue for the normally undeveloped regions of Greece, Bulgaria, Romania, Croatia, Serbia, Bosnia and Slovenia.

On December 14, 2005, Samaritan in-licensed from Three Rivers Pharmaceuticals the Greece & Cyprus Marketing Rights for Amphocil (an amphotericin B cholesteryl sulfate complex for injection indicated for the treatment of invasive aspergillosis, a fungal infection that occurs in immuno-compromised patients). Currently, Samaritan Pharmaceuticals Europe is trying to contract with other pharmaceutical companies to sell and distribute niche, high valued products in the above undeveloped European regions.

Samaritan is a small-cap biotech firm engaged in discovery and development of therapeutics' for AIDS, Alzheimer's, Cancer and Heart disease.